KR20220061026A - Flt3 억제제를 포함하는 백혈병 치료용 약학적 조성물 - Google Patents

Flt3 억제제를 포함하는 백혈병 치료용 약학적 조성물 Download PDF

Info

Publication number
KR20220061026A
KR20220061026A KR1020210149894A KR20210149894A KR20220061026A KR 20220061026 A KR20220061026 A KR 20220061026A KR 1020210149894 A KR1020210149894 A KR 1020210149894A KR 20210149894 A KR20210149894 A KR 20210149894A KR 20220061026 A KR20220061026 A KR 20220061026A
Authority
KR
South Korea
Prior art keywords
flt3
pharmaceutical composition
leukemia
methyl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020210149894A
Other languages
English (en)
Korean (ko)
Inventor
배인환
송지영
최재율
안영길
Original Assignee
한미약품 주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 한미약품 주식회사 filed Critical 한미약품 주식회사
Publication of KR20220061026A publication Critical patent/KR20220061026A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
KR1020210149894A 2020-11-05 2021-11-03 Flt3 억제제를 포함하는 백혈병 치료용 약학적 조성물 Pending KR20220061026A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20200147156 2020-11-05
KR1020200147156 2020-11-05

Publications (1)

Publication Number Publication Date
KR20220061026A true KR20220061026A (ko) 2022-05-12

Family

ID=81458079

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020210149894A Pending KR20220061026A (ko) 2020-11-05 2021-11-03 Flt3 억제제를 포함하는 백혈병 치료용 약학적 조성물

Country Status (8)

Country Link
US (1) US20260102397A1 (https=)
EP (1) EP4241773A4 (https=)
JP (1) JP7842752B2 (https=)
KR (1) KR20220061026A (https=)
CN (1) CN116583284A (https=)
CA (1) CA3197836A1 (https=)
TW (1) TW202233193A (https=)
WO (1) WO2022098083A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101954370B1 (ko) 2018-07-25 2019-03-05 한미약품 주식회사 피리미딘 화합물 및 이를 포함하는 암의 예방 또는 치료용 약학 조성물
BR112021016522A2 (pt) 2019-02-22 2021-10-26 Hanmi Pharm. Co., Ltd. Composição farmacêutica para o tratamento da leucemia mieloide aguda
EA202290154A1 (ru) 2019-06-27 2022-03-29 Ханми Фарм. Ко., Лтд. Фармацевтическая композиция для лечения острого миелоидного лейкоза, содержащая ингибитор flt3 и химиотерапевтические агенты
CN117586344B (zh) * 2022-08-12 2025-07-25 上海交通大学医学院附属瑞金医院 靶向flt3-d835突变的抗原肽及其在肿瘤免疫治疗中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0500492D0 (en) * 2005-01-11 2005-02-16 Cyclacel Ltd Compound
US20110183975A1 (en) * 2008-10-07 2011-07-28 Yasuhiro Goto Novel 6-azaindole aminopyrimidine derivatives having nik inhibitory activity
CN110229142A (zh) * 2014-04-04 2019-09-13 希洛斯医药品股份有限公司 细胞周期蛋白依赖性激酶7(cdk7)的抑制剂
KR102110573B1 (ko) * 2015-08-13 2020-05-13 베이징 한미 파마슈티컬 컴퍼니 리미티드 Irak4억제제 및 이의 용도
KR101954370B1 (ko) * 2018-07-25 2019-03-05 한미약품 주식회사 피리미딘 화합물 및 이를 포함하는 암의 예방 또는 치료용 약학 조성물
KR20200102948A (ko) * 2019-02-22 2020-09-01 한미약품 주식회사 Flt3 저해제 및 iap 길항제를 포함하는 급성 골수성 백혈병의 치료를 위한 약학적 조합물

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
A S Moore et al., Leukemia, 2012, 26, 1462-1470
Cancer Cell, (2007), 12: 367-380
Catherine et al., Nature, 2012, 485, 260-263
Christine et al., Cancer Discovery, 9, (2019), 1050
Current Pharmaceutical Design (2005), 11, 3449-3457
H Kiyoi et al., Cancer Science (2020), 111, 312
Liu et al., Journal of Hematology & Oncology (2017), 10, 145
Yamada T et al., J. Immunol., (2001) 167, 283-288

Also Published As

Publication number Publication date
EP4241773A1 (en) 2023-09-13
JP2023548190A (ja) 2023-11-15
CA3197836A1 (en) 2022-05-12
JP7842752B2 (ja) 2026-04-08
WO2022098083A1 (ko) 2022-05-12
EP4241773A4 (en) 2024-10-16
CN116583284A (zh) 2023-08-11
US20260102397A1 (en) 2026-04-16
TW202233193A (zh) 2022-09-01

Similar Documents

Publication Publication Date Title
Burke et al. Beyond PI3Ks: targeting phosphoinositide kinases in disease
KR20220061026A (ko) Flt3 억제제를 포함하는 백혈병 치료용 약학적 조성물
He et al. Targeting PI3K/Akt signal transduction for cancer therapy
Siveen et al. Role of non receptor tyrosine kinases in hematological malignances and its targeting by natural products
US12378249B2 (en) Isoquinoline compounds and uses thereof
KR101954370B1 (ko) 피리미딘 화합물 및 이를 포함하는 암의 예방 또는 치료용 약학 조성물
US10183941B2 (en) Pyrimidine or pyridopyridone compound and application thereof
EP1708712A1 (en) Treatment of malignant gliomas with tgf-beta inhibitors
EP2531194A1 (en) Identification of lkb1 mutation as a predictive biomarker for sensitivity to tor kinase inhibitors
EP2187967B1 (en) Methods and compositions for treating cancers
UA125216C2 (uk) Комбінована терапія
US20180201606A1 (en) Method of inhibiting dyrk1b
EA024194B1 (ru) Содержащие диарилацетиленгидразид ингибиторы тирозинкиназы
KR20140138927A (ko) Tor 키나제 억제자를 사용하는 암의 치료
EP3860609A1 (en) Combination therapies
KR20160004272A (ko) 전립선암 치료를 위한 디하이드로피라지노-피라진 화합물 및 안드로겐 수용체 길항제를 포함하는 조합요법
US20220202815A1 (en) Treatment of cancer
JP2022521380A (ja) Ｆｌｔ３阻害剤及び低メチル化剤を含む急性骨髄性白血病の治療のための薬学的組成物
EP3928780A1 (en) Pharmaceutical composition comprising flt3 inhibitor and hypomethylating agent for treating acute myeloid leukemia
US20150158854A1 (en) Quinazoline compounds, method for preparing the same and use thereof
KR20160090814A (ko) Jak, cdk 및 pim의 억제제를 포함하는 조합 요법
US20050171182A1 (en) Methods and compositions for use in the treatment of mutant receptor tyrosine kinase driven cellular proliferative diseases
WO2016025651A1 (en) Combinations of an erk inhibitor and a tor inhibitor and related methods
HK40102115A (en) Pharmaceutical composition for treating leukemia comprising flt3 inhibitor
RU2807277C2 (ru) Соединения пиримидина и содержащие их фармацевтические композиции для предупреждения или лечения рака

Legal Events

Date Code Title Description
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 20211103

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20241101

Comment text: Request for Examination of Application